The Impact of Elexacaftor/Ivacaftor/Tezacaftor on Cystic Fibrosis Patients Who Acquire COVID-19 Infection

The combination of medication containing elexacaftor, ivacaftor, and tezacaftor (EIT) has dramatically impacted the treatment and prognosis for patients with cystic fibrosis (CF). Lung function, weight, and self-reported quality of life have improved for many of these patients, but little is known a...

Descripción completa

Detalles Bibliográficos
Autores principales: Miles, Brittany, Chacko, Jay, Zaidan, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578654/
https://www.ncbi.nlm.nih.gov/pubmed/36277555
http://dx.doi.org/10.7759/cureus.29276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578654/
https://www.ncbi.nlm.nih.gov/pubmed/36277555
http://dx.doi.org/10.7759/cureus.29276

Ejemplares similares